{
    "clinical_study": {
        "@rank": "158103", 
        "arm_group": {
            "arm_group_label": "Study Group", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive Sanofi Pasteur's DTaP-IPV-Hep B-PRP~T combined vaccine (investigational vaccine) at 6, 10 and 14 weeks of age."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to describe the immunogenicity and safety of a novel DTaP- IPV-\n      Hep B-PRT~T fully liquid combined hexavalent vaccine (Hexaxim\u2122) administered at 6, 10 and 14\n      weeks of age in infants born to mothers documented to be serum anti-hepatitis B surface\n      antigen (HBsAg) serology negative in India.\n\n      Primary Objective:\n\n        -  To evaluate the immunogenicity of the study vaccine in terms of seroprotection\n           [diphtheria toxoid, tetanus toxoid, poliovirus types 1, 2 and 3, Haemophilus influenzae\n           type b (Hib) polysaccharide (PRP), hepatitis B (Hep B)] and vaccine response for\n           pertussis antigens [pertussis toxoid (PT) and filamentous haemagglutinin (FHA)] one\n           month after the third dose.\n\n      Secondary Objectives:\n\n        -  To further describe the immunogenicity of the study vaccine, before the first dose and\n           one month after the third dose.\n\n        -  To describe the safety after each and any doses of the study vaccine."
        }, 
        "brief_title": "Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diphtheria", 
            "Tetanus", 
            "Whooping Cough", 
            "Hepatitis B", 
            "Poliomyelitis", 
            "Invasive Hib Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cough", 
                "Diphtheria", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Poliomyelitis", 
                "Tetanus", 
                "Tetany", 
                "Whooping Cough"
            ]
        }, 
        "detailed_description": {
            "textblock": "All participants will receive a total 4 doses of Hep B, i.e. one dose of Hep B monovalent\n      vaccine given at birth followed by 3 doses of Sanofi Pasteur's hexavalent vaccine given at\n      6, 10 and 14 weeks of age in the context of the study. Participants and parents will attend\n      four clinic visits; the expected participation in the study is approximately 3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged between 42-56 days (6 to 8 weeks) on the day of inclusion\n\n          -  Born at full term of pregnancy (\u226537 weeks) and with a birth weight \u22652.5 kg\n\n          -  Informed consent form signed by the parent(s) or any other legally acceptable\n             representative\n\n          -  Subject and parent/legally acceptable representative are able to attend all scheduled\n             visits and to comply with all trial procedures\n\n          -  Born to known hepatitis B surface antigen (HBsAg) seronegative mother (documented\n             laboratory result of HBsAg assay from maternal blood sample performed during last\n             trimester of pregnancy available)\n\n          -  Have received one documented dose of Hep B vaccine and oral poliovirus vaccine (OPV)\n             from birth as per national recommendations. Exclusion Criteria:\n\n          -  Participation in another clinical trial in the 4 weeks preceding the trial inclusion\n             or planned participation during the present trial period in another clinical trial\n             investigating a vaccine, drug, medical device, or medical procedure\n\n          -  Receipt of any vaccine in the 4 weeks preceding the first trial vaccination (except\n             Bacillus Calmette-Guerin [BCG] vaccine) or planned receipt of any other vaccine\n             within the period from 8 days before to 8 days after each subsequent trial\n             vaccination\n\n          -  Previous vaccination against the diphtheria, tetanus, pertussis, poliomyelitis\n             (expect the birth dose of OPV as per national recommendations) and hepatitis B\n             (except the birth dose of Hep B vaccine) diseases or Hib infection with the trial\n             vaccine or another vaccine\n\n          -  Past or current receipt of immune globulins, blood or blood-derived products or\n             planned administration during the trial\n\n          -  Known or suspected congenital or acquired immunodeficiency; or receipt of\n             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy\n             since birth; or long-term systemic corticosteroid therapy (prednisone or equivalent\n             for more than 2 consecutive weeks since birth)\n\n          -  History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, or Hib\n             infections (confirmed either clinically, serologically or microbiologically)\n\n          -  Known personal or maternal history of Human Immunodeficiency Virus (HIV) or hepatitis\n             C seropositivity\n\n          -  Known systemic hypersensitivity to any of the vaccine components, or history of a\n             life-threatening reaction to the trial vaccine or a vaccine containing the same\n             substances\n\n          -  Known thrombocytopenia, as reported by the parent/legally acceptable representative\n\n          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,\n             contraindicating intramuscular vaccination\n\n          -  In an emergency setting, or hospitalized involuntarily\n\n          -  Chronic illness that, in the opinion of the investigator, is at a stage where it\n             might interfere with trial conduct or completion\n\n          -  Moderate or severe acute illness/infection (according to investigator judgment) on\n             the day of vaccination or febrile illness (axillary temperature \u226538\u00b0C) on the day of\n             inclusion (a prospective subject should not be included in the study until the\n             condition has resolved or the febrile event has subsided)\n\n          -  Identified as a natural or adopted child of the Investigator, relatives or employee\n             with direct involvement in the proposed study\n\n          -  History of seizures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "8 Weeks", 
            "minimum_age": "6 Weeks"
        }, 
        "enrollment": {
            "#text": "177", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01948193", 
            "org_study_id": "A3L33", 
            "secondary_id": [
                "U1111-1127-6936", 
                "CTRI/2013/09/003997"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Study Group", 
            "description": "0.5 mL, Intramuscular", 
            "intervention_name": "Hexaxim\u2122: DTaP-IPV-Hep B-PRP~T combined vaccine", 
            "intervention_type": "Biological", 
            "other_name": "Hexaxim\u2122"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diphtheria", 
            "Tetanus", 
            "Whooping Cough", 
            "Hepatitis B", 
            "Poliomyelitis", 
            "DTaP IPV-Hep B-PRP~T combined vaccine (Hexaxim\u2122)"
        ], 
        "lastchanged_date": "February 21, 2014", 
        "link": [
            {
                "url": "http://www.sanofipasteur.com"
            }, 
            {
                "url": "http://www.sanofi.com"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ludhiana", 
                        "country": "India", 
                        "state": "Punjab", 
                        "zip": "141008"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pune", 
                        "country": "India", 
                        "zip": "411043"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "1", 
        "official_title": "Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T Combined Vaccine Given at 6, 10 and 14 Weeks of Age in Infants From India Who Previously Received a Dose of Hepatitis B Vaccine at Birth", 
        "overall_contact": {
            "email": "RegistryContactUs@sanofipasteur.com", 
            "last_name": "Public Registry Sanofi Pasteur"
        }, 
        "overall_official": {
            "affiliation": "Sanofi Pasteur SA", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Drugs Controller General of India", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Summary of levels of antibodies to the vaccine antigens following 3 doses of DTaP-IPV-Hep B-PRP~T, Sanofi Pasteur's hexavalent vaccine", 
            "safety_issue": "No", 
            "time_frame": "Day 30 (post 3rd vaccination)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01948193"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Solicited injection site: Tenderness, Redness, and Swelling: Solicited Systemic Reactions: Fever (temperature), Vomiting, Abnormal crying, Drowsiness, Loss of appetite, and Irritability. Unsolicited averse events including serious adverse events.", 
            "measure": "Number of participants reporting solicited injection site reactions, solicited systemic reactions, unsolicited systemic reactions, and serious adverse events after booster administration of DTaP IPV Hep B PRP T vaccine and Infanrix hexa\u2122 vaccine.", 
            "safety_issue": "No", 
            "time_frame": "Day 0 to up to 3 months post-vaccination"
        }, 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi Pasteur, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}